InvestSMART

Invex Therapeutics Ltd (ASX:IXC)

ALERT: Price-sensitive ASX Announcement for IXC
Current share price for IXC : $0.105 -0.015 (-12.50%)+
Announcement
Release
12 Feb 2026 1:34PM
Price at Release
$0.120
Full Release
download
Summary
The half-year report for Invex Therapeutics Ltd, ending 31 December 2025, outlines the company's financial performance and operational highlights. The company reported a net loss of $715,582, a significant increase from the previous corresponding period. The report also details the company's collaboration with Tessara Therapeutics on Exenatide for Alzheimer's Disease, highlighting positive pre-clinical results. Additionally, the company renewed its orphan drug designation for Exenatide in Europe for treating Traumatic Brain Injury. Corporate changes included resignations of key directors and executives. The report concludes with an unqualified review from the independent auditor, asserting the financial report's compliance with Australian accounting standards.
Key Points
  • Net loss for the period was $715,582.
  • Renewed orphan drug designation for Exenatide in Europe.
  • Collaboration with Tessara Therapeutics showed positive results for Exenatide.
  • Significant increase in loss compared to the previous corresponding period.
  • Cash at bank was $4,595,328 as of 31 December 2025.
  • Corporate changes included resignations of directors and executives.
  • No dividends were declared or paid during the period.
  • The financial report was reviewed without qualification by BDO Audit Pty Ltd.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.